From: Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies
No. | Identifier | Date | Endpoint | Page | Number of studies (k) | Effect measure |
---|---|---|---|---|---|---|
1 | N15-06 | 2017-03 | Morning pain | 85 | 5 | OR |
2 | N15-11 | 2017-03 | Ear infection | 62 | 2 | OR |
3 | S15-02 | 2017-01 | Mortality | 53 | 2 | OR |
4 | D15-02 | 2017-01 | Mortality | 74 | 2 | OR |
5 | A16-71 | 2016-12 | Morbidity | 5 | 6 | OR |
6 | A16-38 | 2016-12 | Vomiting | 4 | 2 | RR |
7 | P14-03 | 2016-11 | Breast cancer screening | 55 | 3 | RR |
8 | N14-02 | 2016-08 | Remission from anxiety disorder | 127 | 2 | OR |
9 | A16-30 | 2016-08 | AIDS-defining events | 103 | 2 | RR |
10 | N15-07 | 2016-08 | Ejaculation dysfunction | 89 | 4 | OR |
11 | A16-11 | 2016-06 | Serious adverse events | 86 | 2 | RR |
12 | A10-03 | 2016-04 | Serious adverse events | 89 | 2 | OR |
13 | A15-57 | 2016-02 | St. George’s respiratory questionnaire response | 22 | 2 | RR |
14 | A15-45 | 2016-01 | Morbidity | 24 | 2 | OR |
15 | A15-31 | 2015-11 | Mortality | 87 | 2 | RR |
16 | A15-25 | 2015-10 | Serious adverse events | 89 | 2 | RR |
17 | A15-21 | 2015-07 | Mortality | 16 | 2 | RR |
18 | S13-04 | 2015-05 | Screening for abdominal aortic aneurysm | 71 | 4 | OR |
19 | A15-06 | 2015-05 | Morbidity | 96 | 3 | RR |
20 | A15-05 | 2015-03 | Morbidity | 4 | 2 | RR |
21 | A14-38 | 2015-01 | Serious adverse events | 65 | 3 | RR |
22 | A14-25 | 2014-11 | Serious adverse events | 115 | 2 | RR |
23 | A14-22 | 2014-10 | Transition Dyspnea Index responder | 67 | 2 | RR |
24 | A14-19 | 2014-09 | Urge to urinate | 75 | 3 | RR |
25 | A14-18 | 2014-09 | Persistent virological response (SVR24) | 194 | 3 | RR |
26 | S13-03 | 2014-06 | Participants with cervical intraepithelial neoplasia 3+ | 15 | 6 | RR |
27 | A13-29 | 2013-10 | Metformidosis | 15 | 3 | RR |
28 | A10-01 | 2013-08 | Remissions | 1183 | 2 | OR |
29 | A13-20 | 2013-08 | Visual acuity | 28 | 3 | RR |
30 | S11-01 | 2013-07 | Bowel cancer | 61 | 7 | OR |
31 | A13-23 | 2013-06 | Mortality | 15 | 2 | RR |
32 | A13-05 | 2013-04 | Full recovery | 19 | 4 | RR |
33 | A05-10 | 2013-04 | Cardiovascular death | 75 | 3 | RR |
34 | A12-19 | 2013-03 | Ocular adverse event | 17 | 2 | RR |
35 | A05-18 | 2012-08 | Serious adverse events | 67 | 18 | OR |
36 | A12-10 | 2012-07 | Adverse events | 20 | 3 | RR |
37 | A12-03 | 2012-04 | Loss of transplant | 23 | 2 | RR |
38 | A12-04 | 2012-04 | Virus occurrence | 22 | 3 | RR |
39 | A09-05 | 2012-04 | Alzheimer’s disease assessment scale | 51 | 6 | OR |
40 | A11-30 | 2012-03 | Mortality | 24 | 2 | OR |